New RA Guidelines Upgrade Position of JAK Inhibitors, Biosimilars on Equal Footing with Reference Products

The Japan College of Rheumatology (JCR) has revised its rheumatoid arthritis (RA) treatment guidelines for the first time in six years, making a number of major updates. JAK inhibitors, which were recommended as a “third-stage” treatment in the previous version,...read more